Health Canada has approved Almirall’s Tudorza Genuair aclidinium bromide DPI for the treatment of COPD, Almirall Canada has announced. Forest Laboratories is partnered with Almirall on commercialization of the product in Canada and in the US. The inhaler was approved in the US, where it is called Tudorza Pressair, and in Europe, where it is called Eklira Genuair or Bretaris Genuair, in July 2012.
Almirall Canada General Manager Ed Dybka commented, “We are very proud to bring Tudorza Genuair to COPD patients in Canada. Canadian patients not only have a new treatment option with proven results in managing COPD symptoms, but we’re excited about the innovation behind the Genuair inhaler and believe its ease of use will help patients take their medication correctly and experience improved outcomes.”
Forest Laboratories Canada General Manager Greg Engel added, “We are pleased with the Health Canada approval of Tudorza Genuair. This announcement marks an important milestone in the partnership between Forest and Almirall, demonstrating our united commitment to offer new options to improve the health of Canadians living with COPD.”
Read the Almirall press release.
